Biofrontera 과거 수익 실적
과거 기준 확인 0/6
Biofrontera's earnings have been declining at an average annual rate of -7.5%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 13.8% per year.
주요 정보
-7.5%
수익 성장률
51.5%
EPS 성장률
| Pharmaceuticals 산업 성장 | 6.0% |
| 매출 성장률 | 13.8% |
| 자기자본 수익률 | -123.8% |
| 순이익 | -38.3% |
| 다음 실적 업데이트 | 13 Nov 2024 |
최근 과거 실적 업데이트
Recent updates
Biofrontera Inc.'s (NASDAQ:BFRI) Shares Leap 25% Yet They're Still Not Telling The Full Story
Sep 28
Further Upside For Biofrontera Inc. (NASDAQ:BFRI) Shares Could Introduce Price Risks After 40% Bounce
Aug 09Take Care Before Jumping Onto Biofrontera Inc. (NASDAQ:BFRI) Even Though It's 29% Cheaper
May 24Biofrontera Inc. (NASDAQ:BFRI) Not Doing Enough For Some Investors As Its Shares Slump 28%
Dec 30The Market Doesn't Like What It Sees From Biofrontera Inc.'s (NASDAQ:BFRI) Revenues Yet As Shares Tumble 43%
Nov 13Can Biofrontera (NASDAQ:BFRI) Afford To Invest In Growth?
Oct 18Biofrontera announces preliminary Q3 product revenue, stock falls ~7% after hours
Oct 05Biofrontera gets notice of allowance for U.S. patent covering a nanoemulsion formulation
Sep 06Biofrontera GAAP EPS of -$0.05, revenue of $4.5M; reaffirms FY22 guidance
Aug 12Biofrontera announces 2Q prelim product revenues
Jul 12수익 및 비용 분석
Biofrontera 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
| 날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
|---|---|---|---|---|
| 30 Jun 24 | 35 | -14 | 35 | 1 |
| 31 Mar 24 | 33 | -23 | 38 | 0 |
| 31 Dec 23 | 34 | -20 | 38 | 0 |
| 30 Sep 23 | 34 | -26 | 38 | 0 |
| 30 Jun 23 | 29 | -23 | 38 | 0 |
| 31 Mar 23 | 28 | -14 | 36 | 0 |
| 31 Dec 22 | 29 | -1 | 35 | 0 |
| 30 Sep 22 | 28 | -12 | 24 | 0 |
| 30 Jun 22 | 28 | -26 | 33 | 0 |
| 31 Mar 22 | 29 | -29 | 29 | 0 |
| 31 Dec 21 | 24 | -38 | 26 | 0 |
| 30 Sep 21 | 24 | -23 | 32 | 0 |
| 30 Jun 21 | 22 | -10 | 19 | 0 |
| 31 Mar 21 | 19 | -10 | 17 | 0 |
| 31 Dec 20 | 19 | -11 | 18 | 0 |
| 31 Dec 19 | 26 | -11 | 28 | 0 |
양질의 수익: BFRI is currently unprofitable.
이익 마진 증가: BFRI is currently unprofitable.
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: BFRI is unprofitable, and losses have increased over the past 5 years at a rate of 7.5% per year.
성장 가속화: Unable to compare BFRI's earnings growth over the past year to its 5-year average as it is currently unprofitable
수익 대 산업: BFRI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).
자기자본 수익률
높은 ROE: BFRI has a negative Return on Equity (-123.82%), as it is currently unprofitable.